New hope for hard-to-treat myeloma: experimental drug enters final testing phase
NCT ID NCT07138209
First seen Mar 06, 2026 · Last updated May 13, 2026 · Updated 9 times
Summary
This study tests a new drug called QLS32015 against two standard treatments (pomalidomide with dexamethasone, or selinexor with dexamethasone) in 228 adults with multiple myeloma that has returned or stopped responding to prior therapy. The main goal is to see if QLS32015 alone can delay cancer progression better than the standard options. Participants must be 18 or older and have measurable signs of myeloma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Clinical Research Center for Blood Diseases
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.